Commodity Channel Index
|Bid||23.97 x 1100|
|Ask||24.48 x 800|
|Day's Range||22.51 - 24.14|
|52 Week Range||6.30 - 37.41|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
Is (RCUS) Outperforming Other Medical Stocks This Year?
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 138,000 shares of the Company’s common stock at an exercise price per share of $28.96, which was the closing price on June 8, 2020. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
Gilead's coronavirus drug, remdesivir, could capture nearly $8 billion in 2022 sales, an analyst said Wednesday as he upgraded GILD stock. He sees promise for Gilead in cancer drugs.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Wednesday, June 10, 2020 at 3:50 p.m. Eastern Time.
The global death toll from the coronavirus that causes COVID-19 rose above 380,000 on Wednesday after Brazil recorded its biggest one-day increase since the start of the outbreak, and protests about the death of George Floyd in Minnesota last week spread around the world.
Shares of Gilead Sciences Inc. gained 1.1% in premarket trading on Wednesday after SVB Leerink upgraded the drugmaker to outperform from market perform. Analysts there predict that remdesivir, Gilead's experimental COVID-19 treatment that has received an emergency use authorization from the Food and Drug Administration, will generate annual peak revenue of $7.7 billion in 2022. They are also in support of Gilead's recent investment in Arcus Biosciences Inc. , which gives the drugmaker "critical mass in oncology.". "With these additional opportunities we believe a valuation of $94+ is realistic, perhaps as soon as the company declares its price for commercial sale of remdesivir," SVB Leerink analyst Geoffrey Porges wrote. He expects Gilead to price remdesivir at around $5,000 for a course of treatment, at the list price in the U.S. Gilead's stock is up 12.7% year-to-date, while the S&P 500 is down 4.6%.
There have been a lot of moving parts to the development-stage biopharma in recent weeks. In the last week alone, the business has inked a long-term partnership with Gilead Sciences (NASDAQ: GILD) and announced the pricing of a massive public offering of common stock. Earlier this week, Arcus Biosciences inked a 10-year development deal with Gilead Sciences that includes a $175 million up-front payment for Arcus and an additional $200 million equity investment.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $27.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $302.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences has granted the underwriters a 30-day option to purchase up to 1,650,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on June 2, 2020, subject to customary closing conditions.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering will be sold by Arcus Biosciences. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus' pipeline. The agreement also gives Gilead an equity position in the small-cap, clinical-stage biotech company. Shares of Gilead inched up 0.7% Wednesday on the news, but investors apparently thought Arcus didn't drive a hard enough bargain -- its stock fell 13% to $29.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS), an oncology-focused biopharma, have announced a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline.The agreement will also provide ongoing funding to support Arcus’s research and development programs. On the news GILD shares stayed flat in Wednesday’s pre-market, while RCUS dropped 15%.“We are very pleased to build on Gilead’s growing presence in immuno-oncology,” said Daniel O’Day, CEO of Gilead. “By gaining access to its broad, diverse pipeline and Arcus’s clear strengths in discovery and development, we believe that our partnership with Arcus will significantly accelerate our progress in developing transformative new therapies for cancer.”Upon closing, Arcus will receive a $175M upfront payment and a $200M equity investment from Gilead. Arcus is also eligible to receive up to $1.225B in opt-in and milestone payments. This includes immediate rights to zimberelimab, as well as the right to opt-in to Arcus clinical candidates, upon payment of an opt-in fee ranging from $150M to $275M.If Gilead opts-in to the program for the investigational anti-TIGIT monoclonal antibody AB154, Arcus can receive up to $500M in future U.S. regulatory approval milestones.Gilead will obtain exclusive rights to commercialize any programs outside of the US, for which it will pay tiered royalties from high-teens to low twenties. Gilead will also provide up to $400M in ongoing research and development support over the collaboration term, and can appoint two directors to Arcus’s board.The $200M equity investment will be priced at $33.54 per share. Gilead will also have the right to purchase additional shares from Arcus, up to 35% over the next five years, at a 20% premium at the time the option is exercised, or, if greater, the initial purchase price per share.The transaction is expected to close in the third quarter of 2020.Shares in GILD are up 13% year-to-date, and analysts have a cautious outlook on the stock. The Hold analyst consensus is made up of 8 recent buy ratings vs 16 hold ratings and 4 sell ratings, while the $79 average price target indicates 8% upside potential lies ahead. (See Gilead stock analysis on TipRanks)Related News: Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial Regeneron, Sanofi Get FDA Nod For Dupixent Treatment In Children AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval More recent articles from Smarter Analyst: * Southwest Airlines Prices Two-Tranche $1.8 Billion Debt Offering * AstraZeneca Partners With Accent To Develop Novel Cancer Treatments * Nio Rising On Record-High Monthly Deliveries, Goldman Sachs Upgrade * Inovio Suing Suppliers Over Covid-19 Vaccine Production
Shares of Gilead Sciences Inc. were down 0.4% in premarket trading on Wednesday after the drugmaker said it inked a 10-year deal to develop and commercialize Arcus Biosciences Inc.'s investigational immuno-oncology therapies. Arcus's stock was down 7.5% before the market opened. Gilead will make a $175 million upfront payment and take a $200 million equity stake, and an additional $1.6 billion will be available for milestone payments and R&D funding. Last month people familiar with the matter told Bloomberg News that Gilead was considering a stake in Arcus. The deal is expected to close in the third quarter. Since the start of the year, Gilead's stock has gained 12.6%, after a series of rallies spurred by the market response to its COVID-19 treatment remdesivir getting emergency authorization from the Food and Drug Administration. Year-to-date, shares of Arcus have soared 232.1%, and the S&P 500 is down 7.4%.
Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. The agreement will also provide ongoing funding to support Arcus’s research and development programs.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company’s Board of Directors. Dr. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life-changing and critical quality of life improvement therapies for patients.
We can readily understand why investors are attracted to unprofitable companies. Indeed, Arcus Biosciences (NYSE:RCUS...
CAMBRIDGE, Mass., May 12, 2020 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the first quarter ended March 31, 2020 and provided corporate updates.